Avastin Helps in Lung Cancer
Avastin is first medicine to extend survival beyond one year in patients with previously untreated non-small cell lung cancer , according to a landmark US study published in the New England Journal of Medicine.
The study showed that the median duration of survival in the Avastin plus paclitaxel and carboplatin chemotherapy group was 12.3 months compared to 10.3 months in the group treated with chemotherapy alone.
Overall patients treated with Avastin plus chemotherapy had an approximate 27 percent improvement in survival compared to patients receiving chemotherapy alone.
The results of this study have changed the treatment standard of care for and are an important step forward for patients with advanced lung cancer
